Effekte von R80122 : der einfluss eines neuen Phosphodiesterase-Hemmers auf die globale und intestinale Hämodynamik bei koronarchirurgischen Patienten

Phosphodiesterase III inhibitors have been established in recent years in the therapy of congestive heart failure. Many disadvantages, such as extensive vasodilation and the lack of proven positive inotropic properties combined with thrombepenia and elevation of transaminases, have complicated the handling of the drug in clinical practice